Please login to the form below

Not currently logged in
Email:
Password:

Ann Barbier joins Translate Bio as its chief medical officer

She will take responsibility for leading the US biotech's clinical R&D

Ann BarbierUS-based biotech Translate Bio has appointed Ann Barbier as its new chief medical officer.

She brings 20 years' of drug discovery and development experience to her new role, which will see her take responsibility for leading all clinical research and development, medical affairs and related functions at Translate Bio.

She said: “With near-term clinical programmes in cystic fibrosis and OTC deficiency, Translate Bio is approaching a critical and exciting time.

“Our platform has the potential to be transformative for patients, and I am incredibly excited about the opportunity to join an experienced management team dedicated to finding innovative treatments in areas of high unmet need.”

Prior to joining Translate Bio, Barbier was vice president of clinical development, rare genetic diseases at Agios Pharmaceuticals, where she led the development programme of a small molecule in rare benign haematological diseases.

She has also served Shire in various roles including global clinical development lead and senior medical director, and her career experience has seen her work at Envivo, Johnson & Johnson and Aventis.

15th November 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics